The relationship between the clearance of HBsAg and the remodeling of B cell subsets in CHB patients treated with Peg-IFN-α

Wu, Ziheng; Tan, Lei; Wei, Guoli; Mo, Zhishuo; Chen, Dabiao; Wang, Peipei; Zhao, Qiyi; Xie, Dongying; Gao, Zhiliang

doi:10.21037/atm-21-409

Cited by 7 publications

(6 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of similar studies showed that the anti-HBs-seroconversion rates post-hepatitis B vaccination ranged from 81.8 to 100% in individuals with HBsAg seroclearance after IFNα-based therapy, compared to 0–36.4% in unvaccinated individuals [ 9 , 10 , 15 ]. Patients with CHB who were treated with Peg-IFNα for 24 weeks showed significant increases in memory B and plasma cells, relative to baseline levels [ 17 ]. In contrast, untreated patients with CHB had difficulty producing anti-HBs even when administered multiple hepatitis B-vaccine doses, which may relate to severe B cell dysfunction in patients with CHB [ 18 , 19 ].…”

Section: Discussionmentioning

confidence: 99%

“…The differences in the number of Breg cells were not significant in the non-vaccinated group. Previous reports revealed that, overall, Breg cells increased significantly during the early stage of Peg-IFNα treatment (12–24 weeks) [ 17 , 33 ]. However, Fu et al showed that with extended Peg-IFNα treatment, the proportion of Breg cells gradually decreased, which correlated significantly with a higher HBeAg-seroconversion rate and higher IgG secretion [ 33 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Peg-IFNα combined with hepatitis B vaccination contributes to HBsAg seroconversion and improved immune function

Liu,

Ren,

et al. 2024

Virol J

View full text Add to dashboard Cite

Purpose The purpose of this study was to investigate immunological variations between a group that received the hepatitis B vaccine and a non-vaccine group. We focused on a cohort that achieved HBsAg seroclearance after Peg-IFNα treatment of CHB. Methods We enrolled twenty-eight individuals who achieved HBsAg seroclearance after Peg-IFNα treatment. They were divided into two groups: a vaccine group (n = 14) and a non-vaccine group (n = 14). We assessed lymphocyte subpopulations, B cell- and T cell-surface costimulatory/inhibitory factors, cytokines and immunoglobulin levels were detected at different time points to explore immune-function differences between both groups. Results The seroconversion rate in the vaccine group at 24 weeks post-vaccination was 100%, which was significantly higher (p = 0.006) than that of the non-vaccine group (50%). Additionally, more individuals in the vaccine group exhibited anti-HBs levels exceeding 100 IUs/L and 300 IUs/L compared to the non-vaccine group (p < 0.05). The vaccine group demonstrated significantly increase total B cells and class-switched B cells at 24 weeks and plasma cells, CD80+B cells, Tfh cells, and ICOS+Tfh cell at 12 weeks, compared with baseline levels (p < 0.05). Conversely, Bregs (CD24+CD27+ and CD24+CD38high) decreased significantly at 24 weeks (p < 0.05). None of the above changes were statistically significance in the non-vaccine group (p > 0.05). Total IgG increased significantly in the vaccine group, and IL-2, IL-5, and IL-6 concentrations increased significantly at week 24 (p < 0.05). Differences in various types of cytokines and immunoglobulins in the plasma of the non-vaccine group were not significant (p > 0.05). Anti-HBs titers positively correlated with Th1/Th2 cells at 24 weeks (r = 0.448 and 0.458, respectively, p = 0.022 and 0.019, respectively), and negatively with CD24+CD38highBreg cells (r = -0.402, p = 0.042). Conclusions After achieving HBsAg seroclearance through Peg-IFNα treatment for CHB, administering the hepatitis B vaccine significantly increased anti-HBs-seroconversion rates and antibody levels. We also observed significant immunological differences between the vaccine and non-vaccine groups. Specifically, the vaccine group exhibited significant increases in B cells, plasma cells, and Tfh cells, while Breg levels was significantly lower. These immunological changes are likely conducive to the production of anti-HBs antibodies. However, in the non-vaccine group, the observed changes were not significantlly significant.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Peg-IFNα combined with hepatitis B vaccination contributes to HBsAg seroconversion and improved immune function

Liu,

Ren,

et al. 2024

Virol J

View full text Add to dashboard Cite

show abstract

“…67 The study of B-cell subsets in peripheral blood mononuclear cells from a subset of Everest project patients found that B-cell subsets were reformed after Peg-IFNα treatment in CHB patients and were associated with HBsAg clearance. 68 sCD163 has also been shown to be a useful serum marker of CHB and can be used as a predictor of HBsAg clearance. 69 The results of one study showed that the proportion of baseline mMD-SCs and CD4+ Treg cells in HBeAg-negative CHB patients was REVIEW significantly higher than that healthy people, with the highest proportion in patients who did not achieve HBsAg clearance.…”

Section: Preferred Population and Clinical Indicators That Predict Hb...mentioning

confidence: 99%

Optimal Treatment Based on Interferon No Longer Makes Clinical Cure of Chronic Hepatitis B Far Away: An Evidence‐Based Review on Emerging Clinical Data

Li,

Wang,

Zhou

et al. 2024

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

Chronic hepatitis B (CHB) remains a major global public health problem. The functional cure is the ideal therapeutic target recommended by the latest guidelines, and pursuing a functional cure has become the key treatment end point of current therapy and for upcoming clinical trials. In this review, based on the latest published clinical research evidence, we analyzed the concept and connotation of clinical cures and elaborated on the benefits of clinical cures in detail. Secondly, we have summarized various potential treatment methods for achieving clinical cures, especially elaborating on the latest research progress of interferon‐based optimized treatment strategies in achieving clinical cures. We also analyzed which populations can achieve clinical cures and conducted a detailed analysis of relevant virological and serological markers in screening clinical cure advantage populations and predicting clinical cure achievement. In addition, we also introduced the difficulties that may be encountered in the current pursuit of achieving a clinical cure.

show abstract

“…They are effective for suppressing HBV replication, but not for silencing or eliminating circular DNA; hence, they hardly reduce HBsAg levels, and the overall therapeutic effect is unsatisfactory. Moreover, long-term NUCs antiviral therapy has potential drug-related side effects, psychological burden, relapse from drug withdrawal, and risk of virus resistance [ 17 – 19 ]. IFN exerts direct antiviral and immunoregulatory activities, inhibiting HBV DNA and RNA replication and eliminating virus-infected cells by enhancing the activity of immune cells, including that of cytotoxic T cells and antigen presenting cells, which in turn inhibit viral protein synthesis and the maturation and egress of virus particles.…”

Section: Introductionmentioning

confidence: 99%

Establishment of a multi-parameter prediction model for the functional cure of HBeAg-negative chronic hepatitis B patients treated with pegylated interferonα and decision process based on response-guided therapy strategy

Tang

Zhang

et al. 2023

BMC Infect Dis

View full text Add to dashboard Cite

Background & aims This study aimed to establish multivariate prediction models according to a response-guided therapy (RGT) based strategy at baseline and week 12 and 24 of follow-up to predict the functional cure for HBeAg-negative patients with chronic hepatitis B (CHB) treated with pegylated interferonα (PEG-IFNα). Methods A total of 242 HBeAg-negative patients with CHB were treated with PEG-IFNα for 52 weeks and followed up for 24 weeks. Responses at the end of follow-up (EOF) were defined as hepatitis B surface antigen (HBsAg) loss, and patients were defined as either responders or non-responders. Results The three most meaningful predictors were an age ≤ 40 years, alanine aminotransferase (ALT) levels ≤ 40 U/L, and HBsAg levels ≤ 100 IU/mL at baseline; ALT levels ≥ 80 U/L, anti-HBc levels ≤ 8.42 S/CO, and HBsAg levels ≤ 50 IU/mL at week 12; and ALT levels ≥ 40 U/L, anti-HBc levels ≤ 8.46 S/CO, and HBsAg levels ≤ 0.2 IU/mL at week 24. The response rates of patients with a score of 0–1 and 4–5 at baseline, week 12, and 24 were 13.5%, 7.8%, and 11.7%; and 63.6%, 68.1%, and 98.1%, respectively. At week 12, the cumulative scores were 0–2, 3–4, 5–7, and 8–10 (response rates 5.0%, 18.9%, 41.3%, and 71.4%, respectively). At week 24, the cumulative scores were 0–3, 4–6, 7–10, and 11–15 (response rates: 1.3%, 12.3%, 37.0%, and 92.5%, respectively). At baseline, patients with scores of 0–1 were slightly recommended; at week 12, patients with 0–1 or 0–2 cumulative scores were recommended to stop treatment. At week 24, patients with a score of 0–1 or a cumulative score of 0–6 were recommended to stop treatment. Conclusion We established a multi-parameter prediction model for the functional cure of HBeAg-negative patients with CHB treated with PEG-IFNα.

show abstract

The relationship between the clearance of HBsAg and the remodeling of B cell subsets in CHB patients treated with Peg-IFN-α

Cited by 7 publications

References 39 publications

Peg-IFNα combined with hepatitis B vaccination contributes to HBsAg seroconversion and improved immune function

Peg-IFNα combined with hepatitis B vaccination contributes to HBsAg seroconversion and improved immune function

Optimal Treatment Based on Interferon No Longer Makes Clinical Cure of Chronic Hepatitis B Far Away: An Evidence‐Based Review on Emerging Clinical Data

Establishment of a multi-parameter prediction model for the functional cure of HBeAg-negative chronic hepatitis B patients treated with pegylated interferonα and decision process based on response-guided therapy strategy

Contact Info

Product

Resources

About